Funguria in cancer patients: Analysis of risk factors, clinical presentation and outcome in 50 patients
| Autor: | M. Studena, Stanislav Spanik, J Silva, J Svec, L. Drgona, E. Grey, L. Sevcikova, J. Lacka, Vladimir Krcmery, E. Oravcova, E. Kukuckova |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty medicine.medical_treatment Opportunistic Infections Neutropenia Blastomycosis Candida tropicalis Risk Factors Neoplasms Internal medicine Candida krusei Candida albicans medicine Humans Dysuria Risk factor Fungemia Mycosis Candida Retrospective Studies biology business.industry Candidiasis General Medicine medicine.disease biology.organism_classification Surgery Infectious Diseases Nephrostomy medicine.symptom business |
| Zdroj: | Infection. 24:319-323 |
| ISSN: | 1439-0973 0300-8126 |
| DOI: | 10.1007/bf01743368 |
| Popis: | Fifty cancer patients with funguria of10(5) CFU/ml, dysuria and leukocyturia were retrospectively analyzed for etiology, risk factors and outcome. In 72% of cases Candida albicans and in 28% non-albicans Candida spp. (Candida krusei, Candida tropicalis) and non-Candida spp. yeasts (Blastoschizomyces capitatus) were isolated. Torulopsis glabrata was not found among these patients. The most frequent risk factors were: antibiotic therapy with more than one antibiotic agent (96%), concomitant fungal infection in other localizations than the urinary tract (36%), colonization with the same species (48%), catheterization with urinary catheter or nephrostomy (46%), prophylaxis with quinolones (50%) and previous therapy with corticosteroids (72%). Structural or anatomic malformations of the urinary tract (26%), neutropenia (28%), antifungal prophylaxis with azoles (22%), and diabetes mellitus (12%) were less frequently seen. Thirty of 36 patients treated with systemic antifungals were cured and six were not. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink